ICG-124 is under clinical development by iCell Gene Therapeutics and currently in Phase I for T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia).
FDA accepts Ipsen’s sNDA for mPDAC therapy
The Onivyde regimen will be used as a first-line treatment for metastatic pancreatic ductal adenocarcinoma patients. Credit: Ed Uthman/ Flickr (Creative Commons). The US Food